On September 12, 2022 Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and multispecific antibodies, reported that it is presenting new preclinical data for its GPC3 Flex-NK cell engager antibody in combination with natural killer cells at the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper)’s annual congress in Paris, France on September 12th, 2022 (Press release, Cytovia Therapeutics, SEP 12, 2022, View Source [SID1234619477]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster is available on both Cytovia and ESMO (Free ESMO Whitepaper)’s websites and will be displayed from 9AM-5PM CET and presented from 12PM-1PM CET on Monday, September 12th, 2022 (Poster Session 13, Hall 4, Abstract 756P).
Background: GPC3 is an oncofetal antigen that is highly expressed in HCC while it is hardly expressed in adult normal tissues except placenta. CYT-303 is a multifunctional bispecific NK cell engager built on our Flex-NKTM scaffold, which engages NK cells through NKp46 and targets GPC3 expressed on tumor cells.
Conclusions:
CYT-303 showed dose-dependent HCC tumor growth inhibition in PBNK and iNK cell injected HCC tumor models.
Dose-dependent increases in CYT-303 concentrations in tumor and blood were observed in the PBNK injected HCC tumor model showing the potential for CYT-303 to penetrate solid tumors.
CYT-303 treated animals showed significant decreases in blood PBNKs suggesting CYT-303 may facilitate trafficking of these cells from blood to the tumor.
Bell shaped dose-response observed with CYT-303 monotherapy in the PBNK injected HCC tumor model is consistent with CYT-303 in vitro studies showing similar dose-responses for PBNK and HCC tumor binding and tumor cytolysis.
The linear dose-response observed with CYT-303 combination therapy with iNK cells in the HCC tumor model is consistent with the in vitro linear dose-response observed with iNK combination for cytolysis of HCC tumors.
CYT-303 treatment resulted in reductions in blood AFP levels in both the PBNK and iNK injected HCC tumor models showing the utility of this biomarker for CYT-303 clinical studies.
These CYT-303 preclinical proof-of-concept studies support clinical development of CYT-303 in HCC.